Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
14.16
+0.87 (6.55%)
At close: Sep 26, 2025, 4:00 PM EDT
13.89
-0.27 (-1.91%)
After-hours: Sep 26, 2025, 6:58 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
205
Market Cap
1.98B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
COGT News
- 24 days ago - Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 4 weeks ago - Cogent Biosciences Announces Participation in the Citi Biopharma Conference - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results - Seeking Alpha
- 2 months ago - Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Why Is Cogent Biosciences Stock Trading Higher On Monday? - Benzinga